Anti-angiogenic effect of Biophytum sensitivum is exerted through its cytokine modulation activity and inhibitory activity against VEGF mRNA expression, endothelial cell migration and capillary tube formation

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 3, 2007, Pages 241-250

  Guruvayoorappan, Chandrasekharan ^a   Kuttan, Girija ^a  

^a AMALA CANCER RESEARCH CENTRE   (India)

Author keywords

Angiogenesis; Biophytum sensitivum; Endothelial cell migration; Proinflammatory cytokines; Proliferation; Tube formation

Indexed keywords

BIOPHYTUM SENSITIVUM EXTRACT; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; PLANT EXTRACT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL MOUSE; CAPILLARY; CARCINOGENESIS; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MODEL; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYTOKINES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICROTUBULES; PLANTS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TETRAZOLIUM SALTS; THIAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249110270     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New Eng J Med 285: 1182-1186, 1971.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31, 1995.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Sem Oncol 6 (Suppl. 16): 15-18, 2002.
4. Riasu W. Mechanism of angiogenesis. Nature 386: 671-674, 1997.
5. Liotta LA, Steeg PS. Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
6. Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13: 2195-2202, 1999.
7. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshi J, et al. KDH/Flk-1 is a major regulator of vascular endothelial growth factor- induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30: 1179-1186, 1999.
8. Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A, et al. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10. Circ Res 89: 259-264, 2001.
9. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98: 682-689, 2002.
10. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Meyer AM, Thompson DC, et al. Genetic ablation of Inducible nitric oxide synthase decrease mouse lung tumorigenesis. Cancer Res 62: 6850-6856, 2002.
11. Dicker AP, Williams TL, Grant DS. Targeting angiogenic process by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24 (5): 438-442, 2001.
12. Walsh DA, Pearson CI, Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 3(3): 147-153, 2001.
13. Dempke W, Riec C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127(7): 411-417, 2001.
14. Bussolino F, Mantovani A, Percisco G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22: 251-256, 1997.
15. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 100: 2491-2499, 2004.
16. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor and receptors in tumor specific angiogenesis and malignancies. Integr Cancer Ther 4: 315-321, 2005.
17. Leyon PV, Kuttan G. Effect of Tinospora cordifolia on the cytokine profile of angiogenesis-induced animals. Int Immunopharmacol 4: 1569-1575, 2004.
18. Sunila ES, Kuttan G. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice. Int Immunopharmacol 6: 733-741, 2006.
19. Puri D. The insulinotropic activity of the Nepalese medicinal plant Biophytum sensitivum, preliminary experimental study. J Ethnopharmacol 78: 89-93, 2001.
20. Jachak SM, Bucar F, Kartnig T. Anti-inflammatory activity of Biophytum sensitivum in carrageenin induced rat paw oedema. Phytother Res 13: 73-74, 1999.
21. Guruvayoorappan C, Afira AH, Kuttan G. Antioxidant potential of Biophytum sensitivum extract in vitro and in vivo. J Basic Clin Physiol Pharmacol 17(4): 255-267, 2006.
22. Lin YL, Wang WY. Chemical constituents of Biophytum sensitivum. Chin Pharm 55: 71-75, 2003.
23. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clinical Invest 52: 2745-2756, 1973.
24. Leyon PV, Kuttan G. Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumor specific angiogenesis. J Exp Clin Cancer Res 22(1): 77-83, 2003.
25. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radio response by COX-2 inhibition. Cancer Res 2000; 60: 1326-1331.
26. Pan Q, Kleer CG, van Golen KL, Irani J, Bo Hema KM, Bias C, et al. Copper deficiency induced by angiogenesis. Cancer Res 62: 4854-4859, 2002.
27. Cole SP. Rapid chemosensitivity testing of human lung tumour cells using MTT assay. Cancer Chemother Pharmacol 17: 259-263, 1986.
28. Campling BG, Pym J, Baker HM, Cole SP, Lam YM. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br J Cancer 63: 75-83, 1991.
29. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival promoting signaling and promotes breast tumour growth. Cancer Res 62: 4491-4498, 2002.
30. Rofstad EK, Halsor EF. Vascular endothelial growth factor, Interleukin-8, platelet derived endothelial cell growth factor and fibroblast growth factor promotes angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60: 4932-4938, 2000.
31. Taloor D, Sing AK, Sindhu GS, Pradad PV, Kleinman HK, Maheshwari RK. Inhibition of angiogenic differentiation of human umbilical vein endothelial cell by curcumin. Cell Growth Diff 9: 305-312, 1998.
32. Schwarz M, Murphy PM. Kaposi sarcoma associated herpes virus G protein-coupled receptor constitutively activates NFkB and induces proinflammatory cytokine and cytokine production via a C-terminal signaling determinant. J Immunol 167 (1): 505-513, 2001.
33. Huang S, De Guzman A, Buckano CD, Fidler IJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates constitutive NFkB activity, cytokines. Cell Mol Ther 6: 9-17, 2000.
34. Yoneda J, Kumyasu H, Crupsem MA, Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90: 447-454, 1998.
35. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100 (5): 2645-2650, 2003.
36. Pradeep CR, Kuttan G. Piperine is a potent inhibitor of nuclear factor-kappa B)NF-kappa B), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 4: 1795-1803, 2004.
37. Li J, Luo S, Hong W, Zhou Z, Zou W. Zhonghua ZhongLiu ZaZhi 24(3): 254-256 [Abstract], 2002.
38. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 20: 538-540, 1999.
39. Salgado R, Vermeulen PB, Buoy I, Weytjens R, Huget P, Van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-897, 1999.
40. Salgado R, Benoy I, Weytjens R, VanBockstaele D, VanMerck E, Huget P, et al. Arterio-venous gradients of IL-6, plasma and serum VEGF and dimmers in human cancer. Br J Cancer 87(12): 1437-1444, 2002.
41. Wei LH, Kuo ML, Chen CA, Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT 3 pathway. Oncogene 22: 1517-1527, 2003.
42. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest 87: 986-995, 1991.
43. Stepien HM, Kolomecki K, Pasieka Z, Komorowski J, Stepien T, Kuzdak K. Angiogenesis of endocrine gland tumors- new molecular targets in diagnosis and therapy. Eur J Endocrinol 148: 143-151, 2002.
44. Pasieka Z, Stepien H, Komorowski J, Kuzdak K. Evaluation of the levels of bFGF, VEGF, sICAM-1, sVCAM-1 in serum of patients with thyroid cancer. Recent Res Cancer Res 162: 189-194, 2003.
45. Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Effect of c-Myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 10:1533-1536, 2004.